Compare Kinross Gold Corporation (KGC) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinross Gold Corporation vs Repligen Corporation Common Stock — how do they compare? Kinross Gold Corporation trades at $22.4 (market cap $27.68B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Kinross Gold Corporation is far larger — about 2.5× Repligen Corporation Common Stock's market cap, and Kinross Gold Corporation pays a 0.68% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kinross Gold Corporation for 53 Days and Repligen Corporation Common Stock for 0 Days on average.
| KGC | RGEN | |
|---|---|---|
Market Cap | $27.68B | $11.14B |
Volume | 5,395,404 | 1,259,263 |
Sector | Basic Materials | Health |
52-Week High | $38.06 | $194.57 |
52-Week Low | $22.24 | $102.87 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | $25.76B | $11.02B |
Dividend Yield | 0.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinross Gold (KGC) trades at $22.24, down 5.56% amid production guidance cuts and legal investigations, yet maintains strong fundamentals with robust earnings beats and a 37.52% net margin. Technical indicators show bearish momentum with support at $23, while fundamentals reveal impressive revenue growth from $3.5B in 2022 to $7.05B in 2025, supported by a low P/E of 8.91 and rising cash flow.
The stock presents a value opportunity with a consensus price target of $38.80 (74% upside), but faces near-term headwinds from operational setbacks and legal scrutiny. Long-term prospects remain solid due to gold price strength and shareholder returns, though investors must weigh production risks against valuation appeal.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
